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Abstract 
 
Colonoscopy is the dominant colorectal cancer screening strategy in the United States.  
There are no randomized controlled trials completed of screening colonoscopy, but 
multiple lines of evidence establish that colonoscopy reduces colorectal cancer incidence 
in both the proximal and distal colon.  Colonoscopy is highly operator dependent, but 
systematic efforts to measure and improve quality are impacting performance.  
Colonoscopy holds a substantial advantage over other strategies for detection of serrated 
lesions, and a recent case-control study suggests that once-only colonoscopy or 
colonoscopy at 20 year intervals, by a high level detector, could ensure lifetime protection 
from colorectal cancer for many patients.   
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Introduction and historical perspective on screening colonoscopy 
 
The first printed suggestion of which I am aware that colonoscopy might be an appropriate 
screening test for colorectal cancer was in 1988 by Al Neugut and Ken Forde 1.  Any sense 
of rashness associated with such an idea was based on factors such as the need for sedation 
for colonoscopy compared to sigmoidoscopy, the considerably higher complication rate of 
colonoscopy, the greater technical expertise needed for performance of colonoscopy, and 
the knowledge that colorectal cancer is more common in the left colon.  However, in 1988 
there were already several cross sectional studies of colonoscopy in asymptomatic 
volunteers underway 2-5, and the results were published in 1990 and 1991 2-5.  These 4 
studies eventually totaled just over 1000 patients 2-6, and demonstrated that the prevalence 
of adenomas in asymptomatic persons is substantial, age-related, and higher in males 2-6.  
During the 1990s it was common for the relative merits of colonoscopy and sigmoidoscopy 
to be debated by experts at national meetings, and clinicians in practice began to commonly 
perform what was in reality screening colonoscopy but which was labeled as diagnostic 
colonoscopy for trivial symptoms of bleeding and change in bowel habits.  This approach 
secured reimbursement, which was not then available for screening colonoscopy. 
 
In the year 2000, two pivotal multicenter trials confirmed the prevalence of adenomas and 
cancer in asymptomatic average risk persons 7, 8, and established that screening 
colonoscopy could be safely performed.  These trials were VA Cooperative Study 380 7 
and the results of screening colonoscopy performed on Eli Lilly employees, retirees, and 
their spouses in several Indianapolis hospitals 8.  These studies confirmed that many 
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patients with advanced proximal colonic neoplasia detected at screening colonoscopy had 
no polyps or neoplasia of any type in their distal colon 7, 8. 
 
The studies were followed by intense lobbying of Congress by gastrointestinal professional 
societies for approval of screening colonoscopy.  It was common to draw the analogy of 
"why would a woman choose to have only one breast examined by mammography?" when 
both breasts are at risk for cancer.  Why then would a patient choose to have the left colon 
examined, and leave the right colon unexamined examined?  The logic of such arguments, 
combined with the observational evidence that advanced right colon neoplasia was 
frequently unaccompanied by left colon neoplasia, resulted in the United States Congress 
passing legislation directing The Center for Medicaid and Medicare Services to cover 
screening colonoscopy for all beneficiaries age 50 and older every 10 years.  This law 
became active on July 1, 2001, and initiated not only rapid growth in screening 
colonoscopy, but transformation of gastrointestinal medicine in the United States.  
Gastroenterologists actively sought out new partners to meet the demand for screening 
colonoscopy, hired physician extenders to attend clinics, and sometimes gave up more 
complex, time consuming and risky procedures such as endoscopic retrograde 
cholangiopancreatography. 
 
The wave of enthusiasm for screening colonoscopy was irresistible, aligning with the 
interests of American patients who generally seek out the most effective and comfortable 
procedure available for screening, and the financial incentives of endoscopists and 
ultimately anesthesia providers. 
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Yet since its inception nearly 3 decades ago, the use of colonoscopy screening for average 
risk persons has had detractors both within and outside the United States.  While 
colonoscopy has come to dominate colorectal cancer screening in the United States, and 
has spread to Germany, Poland, Italy, and to some extent is used in many advanced 
countries. Cost and lack of endoscopic resources are major barriers to increasing use of 
colonoscopic screening in other nations and many prefer screening with fecal occult blood 
testing, particularly fecal immunochemical testing. Detractors have argued that no 
randomized controlled trial of screening colonoscopy is available, and in 2001 there were 
no results published of randomized trials of flexible sigmoidoscopy.  Reasoning that high 
level evidence for screening colonoscopy in average risk persons is still lacking, 4 
randomized controlled trials comparing colonoscopy to fecal immunochemical testing 
have been organized, including one in the U.S. Veterans Administration system.  The 
results of all these trials are pending, and only the results of the first round of screening 
from one of the studies are published 9. 
 
In essence, the United States undertook an enormous, expensive, non-nationalized (except 
for reimbursement), non-quality controlled effort to apply screening colonoscopy to 
colorectal cancer prevention.  This effort was founded on low level evidence consisting of 
observational cross-sectional studies, combined with faith and passion.  
 
Now 13 years into the American experiment in screening colonoscopy, it is fair to ask 
whether the experiment has been successful.  Has screening colonoscopy lowered the 
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incidence and mortality of colorectal cancer, and particularly right-sided colorectal cancer?  
Have other less invasive and less expensive forms of screening progressed to the point they 
should supplant screening colonoscopy?  Are there aspects of American screening 
colonoscopy, and colonoscopy in general, that can be improved?  Has screening 
colonoscopy saved more people than it harmed?  Was average-risk screening colonoscopy 
a success or a mistake? 
 
 
What is the best question to ask about efficacy of screening colonoscopy? 
 
Limited understanding of the biology of colorectal cancer lead to the logical, but incorrect 
assumption that preventing left-sided and right-sided colorectal cancer would be equally 
easy.  The basic principles of inspection, detection, and endoscopic resection seemed 
similar for both sides of the colon.  However, in the past 2 decades it has become clear that 
the molecular basis of colorectal cancer is complex, and that the precursor lesions of cancer 
vary by histology and morphology in the right versus left colon.  For example, for Paris 
classification type II lesions (flat and depressed lesions), the distribution of these lesions is 
shifted toward the right colon 10.  In addition, a hypermethylation or serrated pathway 
occurs primarily in the right colon 11, and the precursor lesion (the sessile serrated polyp 
or sessile serrated adenoma) is universally flat or sessile, consistently similar in color to 
the surrounding normal mucosa 12, 13, and more subject to failed detection and incomplete 
resection compared to conventional adenomas 14, 15.  These factors, if appreciated in 2000, 
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might have raised alarms that perhaps the benefits of flexible sigmoidoscopy cannot be 
easily extrapolated to the proximal colon. 
 
Further, we now have 2 completed randomized control trials showing that sigmoidoscopy 
does reduce distal colon cancer incidence and mortality 14, 15.  Since sigmoidoscopy is 
considerably less expensive than colonoscopy, does not require sedation, and has a lower 
complication rate, the key question is not whether colonoscopy prevents colorectal cancer, 
but whether it prevents right-sided colorectal cancer.  The following section reviews 
available evidence regarding the effect of colonoscopy on overall colorectal cancer 
incidence and mortality, as well the more relevant issue of the effect of colonoscopy on 
proximal colorectal cancer incidence and mortality. 
 
Evidence that colonoscopy prevents overall incident colorectal cancer and cancer 
mortality. 
 
 
Evidence from randomized controlled trials of fecal occult blood testing 
 
The first randomized controlled trial to establish that colorectal cancer screening works 
was conducted by the University of Minnesota and published in 1993 16.  As with all FOBT 
trials, patients with positive tests underwent colonoscopy.  While colorectal cancer 
mortality reductions can be attributed to detection of early stage cancers followed by 
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endoscopic or surgical treatment, incidence reductions in colorectal cancer are attributable 
only to polyp or large polyp detection followed by colonoscopic polypectomy. 
 
In 2000, Mandel et al reported that the 2 screened arms of the trial (which had been 
randomized to annual vs biennial rehydrated guaiac based FOBT with a 3rd arm assigned 
to no screening), had statistically significant 20% and 17% reductions, respectively, in 
incident colorectal cancer compared to the non-screened group 17. 
 
 
Evidence from the randomized controlled trials of sigmoidoscopy 
 
In 2010, Atkin et al reported a randomized controlled trial of once only flexible 
sigmoidoscopy screening compared to no screening in the UK 18.  The risk of proximal 
colorectal cancer in the screened group was 0.97 (95% CI 0.80-1.17) compared to the non-
screened group.  However, only 5% of attendees were referred for colonoscopy, because 
of relatively strict criteria for patient selection for colonoscopy.  In this context, flexible 
sigmoidoscopy screening did not impact the identification of patients with proximal colon 
cancer. 
 
In 2012, Schoen et al reported the results of a randomized controlled trial of flexible 
sigmoidoscopy versus no screening in the PLCO (prostate, lung, colon, ovarian) study in 
the United States 19.  Using more liberal criteria for referral of sigmoidoscopy patients for 
colonoscopy, 21.9% of attendees were referred for colonoscopy.  The proximal colon 
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cancer incidence was 0.86 (95% CI 0.76, 0.97) compared to the non-screened group.  This 
result supports a benefit for colonoscopy in reducing proximal colon cancer incidence, 
since colonoscopy is the only apparent mechanism for the reduction. 
 
 
Evidence from adenoma cohorts 
 
When the U.S. Congress voted to cover screening colonoscopy for Medicare beneficiaries, 
the most heavily utilized studies in lobbying efforts were not the 2000 screening 
colonoscopy studies, but the National Polyp Study 20.  The National Polyp Study was a 
randomized controlled trial testing whether patients with adenomas could undergo their 
first followup surveillance at 3 years rather than 1 year 21.  In 1993 Winawer et al reported 
that the observed incidence of colorectal cancer in the overall cohort was reduced by 76 to 
90% relative to the expected risk in 3 reference populations 20.  These data suggested that 
colonoscopy was almost universally effective in preventing colon cancer, and while these 
results 20 from an adenoma cohort represent a low level of evidence, they were widely 
quoted to support the rationale for screening colonoscopy.  In 2012, Zauber et al reported 
that at a mean of 15.8 years of follow-up, there was a 53% reduction in death from 
colorectal cancer in the cohort compared to reference populations (12 deaths in the study 
versus 25.4 expected deaths) 22.  What is perhaps most impressive about these data is that 
57.3% of the cohort had advanced adenomas at their baseline colonoscopy, a rate about 10 
times higher than the rate of advanced adenomas typically seen in average risk cohorts.  
These risk reductions were achieved despite the very high risk of the cohort. 
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Cohort studies on overall incidence and mortality of colorectal cancer 
 
In 2010 Singh et al from Manitoba, Canada reported a significant 29% reduction in overall 
colorectal cancer mortality associated with a colonoscopy in a non-screening population 
23.  Data from Canada has been criticized because most colonoscopy there is performed by 
general surgeons 24, and virtually every study that has examined the issue has found that 
gastroenterologists on average are more effective than general surgeons in preventing 
incident colorectal cancer 24-27. 
 
In 2009 Kahi et al evaluated the long-term follow-up of volunteers in the original Indiana 
screening colonoscopy study 28.  Prior to the year 2000, this was the largest average risk 
screening colonoscopy trial available for evaluation.  There was a 67% reduction in the 
overall incidence of colorectal cancer in a screening cohort compared to the Surveillance 
End Epidemiology Results (SEER) cohorts, though 6 of 7 observed cancers occurred in the 
proximal colon. 
 
 
Case-control studies on overall incidence of colorectal cancer 
 
Case-control design is generally considered a more powerful form of evidence than cohort 
studies.  Three recent case-control studies 29-31, including 2 performed in screening trials 
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30, 31, have shown very substantial reductions in risk after colonoscopy, ranging from 77% 
to 91%.  These trials were performed in the U.S. and Germany, where colonoscopy is 
performed largely by gastroenterologists. 
 
 
Case-control studies on overall mortality from colorectal cancer 
 
Case-control studies in non-screening populations have shown overall reductions in 
mortality from colorectal cancer of 37% in Canada 32, 44% in the Netherlands 33, and 60% 
in the United States 26. 
 
 
Case-control studies of colonoscopy on right-sided incidence and mortality 
 
Initial trials from Canada failed to demonstrate a reduction in right-sided cancer incidence 
or mortality associated with colonoscopy in non-screening populations 23, 32.  However, in 
the U.S. and Germany, where colonoscopy is performed largely by gastroenterologists, 
colonoscopy has produced consistent reductions in incidence (27 to 42%) 29, 34 and 
mortality (53-56%) 26, 34, and a right-sided incidence reduction associated with screening 
colonoscopy was observed in a German case-control study of 78% 31. 
 
Evidence from variable detection. 
 
12 
 
The adenoma detection rates of endoscopists, including those within groups of 
gastroenterologists, vary widely 35-38.  No substantial study examining adenoma detection 
rates has ever shown a less than 2.5 fold difference between the highest and lowest 
detectors in the same group, and this variation has ranged to up to 8 fold 35-38.  If 
colonoscopy has no impact on colorectal cancer incidence, then the risk of post 
colonoscopy cancer should not vary between endoscopists with different detection rates.  
However, in the screening colonoscopy study from Poland, the hazard ratio for 
development of cancer after colonoscopy performed by gastroenterologists with adenoma 
detection rates below the recommended threshold of 20% was consistently much higher 
than the risk of colorectal cancer in patients colonoscoped by doctors with adequate 
adenoma detection rates 39.  In a recent study from Northern California Kaiser Permanente, 
the risk of cancers after colonoscopy was examined for 136 gastroenterologists whose 
patients suffered 714 interval cancers 40.  The patients of doctors in the highest adenoma 
detection rate quintile had a 0.52 risk of interval cancer compared to patients of doctors in 
the lowest ADR quintile.  There was a 3% reduction in incidence and a 5% reduction of 
mortality for each 1% increase in the adenoma detection rates of the doctors.  These effects 
were present for proximal and distal colon cancers, men and women, early and late stage 
cancers, and regardless of screening, surveillance or diagnostic indications for 
colonoscopy.  These data also indicate that screening colonoscopy prevents both distal and 
proximal colorectal cancer. 
 
 
Evidence from population trends on incidence and mortality 
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Declines in colorectal cancer mortality began in the United States in 1975.  In 2010, 
Edwards et al examined these trends and attributed 12% to improved treatment, 32% to 
changing patterns in risk factors, and 53% to increases in screening 41.  In 2014, the US 
Centers for Disease Control described accelerations in the decline of colorectal cancer 
incidence beginning in 2001 and corresponding to the availability of screening 
colonoscopy in the United States 42.  There was a 3.4% annual decline in incidence during 
the interval 2001-2010, including a 3.9% incidence decline in the screening eligible age 
group of 50 to 75 years and a 1.1% per year incidence increase in age less than 50.  The 
overall decline in colorectal cancer incidence during that interval was 30%, and 
corresponded to an increase in screening rates from 19% in 2000 to 55% in 2010.  
Screening rates were 55% in the 50 to 64-year age group and 64% in the age eligible 
Medicare population of > 65 years 42. 
 
Taken together, these lines of evidence provide near certainty that colonoscopy prevents 
both overall and right sided colorectal cancer and mortality. 
 
 
Advantages of screening with colonoscopy relative to other strategies 
 
Colonoscopy is widely viewed in the U.S. as a comfortable procedure, which in addition 
to its capacity to examine the entire colon, has contributed to the progressive decline in 
flexible sigmoidoscopy screening.  Patients within the same practice who were screened 
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with unsedated flexible sigmoidoscopy were more than twice as likely to say they would 
not be screened again compared to patients screened with sedated colonoscopy 43.  The use 
of propofol for sedation in combination with carbon dioxide insufflation has allowed many 
patients to have a painless procedure and post-procedure experience and function normally 
(except driving is usually not allowed) on the same day as the procedure. 
 
The major advantage of colonoscopy remains its unmatched potential for detection of 
precancerous lesions, and its ability to detect cancer is matched only by CT colonography.  
CT colonography has not been well received because it still requires bowel preparation to 
approach colonoscopy for polyp detection, its high cost as a strategy, and the risks 
associated or believed to be associated with radiation. 
 
Colonoscopy appears to hold a substantial advantage for detection of serrated lesions.  
These lesions are not well seen at CT colonography 44, 45, and CT colonography trials never 
report serrated lesions as a separate outcome.  Absence of blood vessels on the surface of 
serrated lesions has long led to suspicion that guaiac based FOBT and FIT could not detect 
them, which proved completely true when finally tested 46.  Only fecal DNA has shown 
some sensitivity for serrated lesions among non-invasive tests 46. 
 
A major advantage of colonoscopy is the potential for long lasting protection from cancer.  
Of available tests, only colonoscopy is recommended at 10 year intervals 47.  Case-control 
studies of screening sigmoidoscopy identified protection against left-sided cancer 
following sigmoidoscopy of 10 and 16 years, which were the longest periods for which 
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protection was assessed 48, 49.  A recent case control study of colonoscopy in Germany 
found that protection against colorectal cancer remained substantial for more than 20 years 
50.  If intervals between screening can be linked to the adenoma detection rates of 
examiners, this evidence suggests the possibility that patients could have life-long 
protection from a single negative colonoscopy by a high detecting colonoscopist at about 
age 60, or perhaps two examinations at ages 50 and 70 years. 
 
 
Disadvantages of colonoscopy as a screening strategy 
 
In the past patients who had never undergone colonoscopy listed fear of the procedure as 
the major deterrent, but today both those who have and have not undergone colonoscopy 
consider the need for bowel preparation the major problem with the procedure 51.  The 
advent of split-dosing and low volume preparations has improved tolerability, but low 
volume preparations may not adequately prepare all patients and a stratified approach to 
assigning preparations (based on known predictors of inadequate preparation) is the best 
way to optimize rates of adequate preparation.  Much more work is needed to find 
preparations that optimize efficacy, tolerability and safety. 
 
Colonoscopy has high complication rates for a screening test.  Although the efficacy of 
colonoscopy outweighs its harms on a population basis, the occurrence of non-
polypectomy induced perforation, aspiration, or splenic injury in asymptomatic patients is 
costly when viewed from an individual patient perspective and occasionally tragic.  
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Colonoscopists should be well trained in avoidance of complications and fully capable and 
prepared to manage complications. 
 
There is increasing awareness in the U.S. that colonoscopy charges are often too high.  
High charges and in some regions limited capacity are major challenges to the dominance 
of screening colonoscopy.  A principle culprit in the cost trend is hospitals, which charge 
high fees that have little or no transparency or association with actual costs.  The rising use 
of anesthesia specialists for sedation contributes to the trend.  Experience in California with 
reference payment has demonstrated that many centers can perform colonoscopy profitably 
for charges considerably lower those to which they are accustomed.  Bundled payment in 
which colonoscopists share the risk of factors such as anesthesia charges, pathology 
charges, repeat procedures for poor preparation, etc. has been effectively implemented by 
a single large practice in Minnesota 52, and is under evaluation by the Centers for Medicare 
and Medicaid services.  Even at high charges, colonoscopy remains a cost effective 
colorectal cancer screening strategy, as do all of the available tests 53.  This high level of 
cost-effectiveness has been created in part by the enormous costs of cancer care in the 
United States which are substantially greater in absolute terms that the cost of colorectal 
cancer screening 54.  While efforts to improve the cost-effectiveness of colonoscopy and 
colorectal cancer screening are appropriate, it seems also important to limit the high 
pharmaceutical and care costs associated with end of life colorectal cancer care. 
 
A major disadvantage of colonoscopy as a screening strategy is operator dependence 35-40.  
While the adenoma detection rate has been demonstrated to predict protection from post 
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colonoscopy cancer 39, 40, it has also been shown to be remarkably variable within groups 
of gastroenterologists 35-38.  Correcting low-level performers has been challenging 38, 
though recent evidence suggests that training targeted to lesion recognition skills and 
colonoscopy withdrawal skills will consistently improve performance 55, 56.  The advent of 
high definition colonoscopy 57 and split dosing of bowel preps 58 produces detection gains, 
and tools such as chromoendoscopy 59 and electronic chromoendoscopy 60 could be 
mandated by groups for their low-level detectors in an effort to improve performance. The 
recognition of variable performance has fostered a major movement in the gastroenterology 
community to measure and improve colonoscopy quality 61, 62, but there is currently no 
means of mandating quality measurements in American colonoscopy practice.  There is 
little evidence of movement toward quality measurement within the non-GI community 
performing colonoscopy, and this group has lower performance on average for detection 
of adenomas 63 and prevention of colorectal cancer 24-27 compared to gastroenterologists.  
Awareness of post colonoscopy cancer and the general phenomenon of missing lesions 
during colonoscopy have also been used as an excuse for shortening surveillance intervals 
and systematic performance of screening colonoscopy at 5-year intervals 64.  Overuse of 
colonoscopy of course substantially reduces cost-effectiveness. 
 
A final significant disadvantage of colonoscopy is the current dysfunctional post 
polypectomy surveillance strategy, which results in overuse of surveillance in some of the 
patients who need it least, and which provides financial incentives for the wrong set of 
behaviors in colonoscopists.  The problems begin with failure to match the quality of the 
baseline examination sufficiently to the surveillance intervals.  Surveillance 
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recommendations suggest that an examination to the cecum with an adequate preparation 
can be based solely on the findings of precancerous lesions.  However, the findings of 
precancerous lesions are more dependent on the endoscopist than the preparation or the 
cecal intubation 35-38.  Since the surveillance intervals are to be applied uniformly without 
consideration of the adenoma detection rate of the endoscopist, a high performing 
endoscopist (high ADR) will clear patients’ colons better at the baseline examination and 
bring them back more frequently, providing a sort of double protection against colorectal 
cancer to their patients 65.  Most of the protection afforded by colonoscopy is certain to be 
related to the quality of the baseline examination.  On the other hand, a low performing 
endoscopist (low ADR) tells many patients they have a normal colon when they do not, 
and assigns a long interval for surveillance.  This provides a sort of double lack of 
protection for the patient who is unwittingly pleased to hear that their colonoscopy is 
normal.  It would be very useful to find ways to integrate adenoma detection rates into the 
post polypectomy surveillance process, and stratify risk and surveillance intervals 
according to baseline performance.  Realizing that economic factors underlie the behavior 
of most humans, the financial rewards for colonoscopy should be reformed as they 
currently incentivize "one and done" performance of colonoscopy (removing one polyp 
during a colonsoscopy and then not searching carefully for other polyps) and overuse of 
surveillance and screening.  A second problem with post polypectomy surveillance 
intervals is that the risk stratification is likely not optimized. In the current United States 
guidelines, any individual with 3 or more adenomas is recommended to have repeat 
colonoscopy in 3 years 66.  However, recent evidence suggests that 3 or more small or 
diminutive adenomas is a quite different risk predictor compared to when one or more of 
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those lesions is large 67, 68.  As emphasis on adenoma detection rates and the availability of 
high definition colonoscopes increases, detection of individuals with multiple or numerous 
adenomas, all of which are diminutive, is likely to increase.  Coupled with awareness of 
adequate baseline ADR, there is increasing evidence that at least those with 3 or 4 small or 
diminutive adenomas have risk similar to individuals with 1 or 2 small adenomas 67, 68.  It 
is quite possible that some risk stratification should be based on diminutive versus small 
adenomas.  Thus, it is possible that in the hands of a high-level detector, the presence of 
several diminutive adenomas is usually little more than a normal variant. 
 
 
Summary and new directions for screening colonoscopy 
 
Despite a lack of randomized controlled trials, overwhelming evidence indicates that 
colonoscopy has had a major and positive impact on colorectal cancer incidence and 
mortality in the United States, including its application as a screening test.  Advances in 
fecal blood testing (FIT) and tests that combine FIT with fecal DNA assays have become 
the first serious challenges to colonoscopy as the most effective test from a programmatic 
perspective.  Results on the program sensitivity of these tests (FIT and FIT/fecal DNA) are 
awaited with great interest.  From a single time test perspective, colonoscopy is still the 
most effective strategy for detection of precancerous lesions, including large conventional 
adenomas and large serrated lesions.  Because colonoscopy is operator dependent, there is 
little doubt that colonoscopy by a high-level detector is still the most effective colorectal 
cancer prevention strategy available to patients. 
20 
 
 
While the effectiveness of other strategies has improved, colonoscopy has also improved.  
New concepts such as low-volume bowel preparation, split dose preparation, high 
definition colonoscopy, wide-angle colonoscopy, the adenoma detection rate, and the 
importance of the serrated pathway have all produced significant advances in colonoscopy.  
There is considerable room for further improvement to improve patient convenience, 
reduce operator dependence, improve overall efficacy, improve cost-effectiveness, and 
reduce complications (Table 1).  Colonoscopy's position as a central aspect of 
gastrointestinal medicine is in question only with regard to its position as a screening test, 
and as to whether its general application reflects the best data available and the best 
common sense with regard to financial incentives.  If we continue to investigate methods 
to improve colonoscopy, resist financial pressures, and use common sense and courage, we 
can refine colonoscopy and define its story as the most effective visceral cancer prevention 
story ever told.  Whether it remains the dominant screening test, or the tool by which the 
benefits of other screening tests are realized, is a secondary concern.  
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